Grant Amount: Approximate Total Fiscal Year Funding - $600,000.00. The main goal of this program is to strengthen the capacity of indigenous organizations to develop and deliver science-based HIV and STI risk reduction interventions for mobile (mostly Haitian) populations, improve linkages to HIV/STI/TB treatment and care, and increase their understanding about the benefits of early treatment.
Grant Amount: Approximate Total Fiscal Year Funding $4,000,000. Twenty-five percent of adults 15-49 years of age in Botswana are HIV-positive. Voluntary Medical Male Circumcision (VMMC) is one of the key prevention strategies for control of HIV. The goal of this funding opportunity announcement (FOA) is to assist the Government of Botswana in its VMMC activities over the next 5 years. There are two main activities to be implemented.
Grant Amount: Approximate Total Fiscal Year Funding $7,349,997.00. With 17% of the general population infected with HIV, Botswana has one of the highest prevalence rates in the world. Historically, the country has also had a high incidence of TB. The Government of Botswana has developed some of the strongest treatment and prevention of mother to child transmission of HIV (PMTCT) programs in sub-Saharan Africa. As PEPFAR Botswana transitions to a technical assistance (TA) model, there is an increasing focus on the training and mentoring of health care workers to build local capacity.
Grant Amount: Approximate Total Fiscal Year Funding: $4,500,000. The purpose of this FOA is to support the implementation of integrated HIV/AIDS prevention, care and treatment programs in the Republic of Mozambique.
Grant Amount: Approximate Total Fiscal Year Funding: $10,000,000. The purpose of this funding opportunity announcement (FOA) is to support district health teams and health facilities to accelerate provision of comprehensive and high quality HIV/AIDS services in western and west-Nile districts of Uganda in order to ensure continuity of services, minimize new infections and improve the quality of life of people living with HIV.
Grant Amount: Approximate Total Fiscal Year Funding: $3,000,000. Within CDC Central America’s objective of strengthening sustainable key population services within a technical assistance framework, the purpose of this FOA is to support concrete efforts that assist Ministries of Health in Central America to lead manage, coordinate, and implement national responses to their respective concentrated epidemics while sustaining programmatic quality and coverage goals.
Grant Amount: Approximate Total Fiscal Funding: $11,000,000. The PEPFAR program goal and objectives relevant to this FOA in Swaziland are to improve human and institutional capacity of the MOH and NGOs to respond to the HIV epidemic.
Grant Amount: Average One Year Award: $1,500,000.00. Lesotho has a generalized HIV epidemic with a national adult prevalence of 23.3%. The prevalence of tuberculosis (TB) is 632 per 100,000, where 80% of patients identified with tuberculosis are co-infected with HIV. In recognition to the challenge, the Government of Lesotho (GOL) has revised the National HIV/AIDS Strategic Plan and embarked on scale up of HIV prevention, care and treatment services. The provision of quality laboratory is critical.
Grant Amounts: Approximate Total Fiscal Year Funding: $2,950,000. Botswana has both a high prevalence of HIV (25% among persons 15-49 years of age) and a high incidence of TB (455 new cases per 100,000 population per year). Drug resistance is a concern with both diseases. High quality surveillance and monitoring data are needed for effective disease control efforts. This funding opportunity announcement (FOA) has two primary objectives. Both are meant to support ongoing efforts of the Botswana Ministry of Health (MOH).
Grant Amount: Approximate Total Fiscal Year Funding: $1,000,000.00. The program goal and objectives relevant to this FOA in Burma and Papua New Guinea are to support laboratory systems strengthening needs to provide high quality diagnostic testing and clinical services for persons living with HIV/AIDS (PLHA) in these countries.